Paul Rennie Purchases 95,300 Shares of Paradigm Biopharmaceuticals Limited (ASX:PAR) Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie acquired 95,300 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average price of A$0.21 ($0.14) per share, for a total transaction of A$20,108.30 ($13,495.50).

Paradigm Biopharmaceuticals Price Performance

The company has a quick ratio of 5.93, a current ratio of 7.22 and a debt-to-equity ratio of 1.00.

Paradigm Biopharmaceuticals Company Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.